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BloodGenome-wide association studies have nominated many genetic variants for common human traits, includ-
ing diseases, but in many cases the underlying biological reason for a trait association is unknown. Subsets of
genetic polymorphisms show a statistical association with transcript expression levels, and have therefore
been nominated as expression quantitative trait loci (eQTL). However, many tissue and cell types have spe-
ciﬁc gene expression patterns and so it is not clear how frequently eQTLs found in one tissue type will be rep-
licated in others. In the present study we used two appropriately powered sample series to examine the
genetic control of gene expression in blood and brain. We ﬁnd that while many eQTLs associated with
human traits are shared between these two tissues, there are also examples where blood and brain differ, ei-
ther by restricted gene expression patterns in one tissue or because of differences in how genetic variants are
associated with transcript levels. These observations suggest that design of eQTL mapping experiments
should consider tissue of interest for the disease or other traits studied.
Published by Elsevier Inc. Open access under CC BY license.Introduction
Genome-wide association (GWA) studies have provided novel in-
sights into human traits by identifying single nucleotide polymor-
phisms (SNPs) associated with disease, including type 1 diabetes,
coronary artery disease, HIV-1 infection and type 2 diabetes (Fellay
et al., 2007; Preuss et al., 2010; Scott et al., 2007; Sladek et al., 2007;
Steinthorsdottir et al., 2007; Todd et al., 2007; Yang et al., 2010;
Zeggini et al., 2008), or other phenotypes. Because GWAS identify
loci rather than functional variants, most GWAS have provided limit-
ed insights into underlying mechanisms (Hindorff et al., 2009).
Therefore, annotating the possible functional effects of genetic risk
variants is important in understanding genomic data.xpression Unit, Laboratory of
t Drive, Bethesda MD 20892-
n).
irect.com).
C BY license.Mapping of expression quantitative trait loci (eQTL) is one way to
demonstrate that a risk variant within a locus has a functional effect
on gene expression (Cheung et al., 2005; Morley et al., 2004; Myers
et al., 2007; Stranger et al., 2007). eQTL analysis is performed by ex-
amining the association of each SNP with expression of mRNA tran-
scripts. In general, eQTL effects are stronger for SNPs and transcripts
that are physically close to each other (Gibbs et al., 2010). Trait asso-
ciated SNPs from GWAS have been proposed to be more likely associ-
ated with expression differences than other SNPs (Nicolae et al.,
2010). Such studies have generally been performed with transformed
cell lines but eQTLs can also be identiﬁed in liver (Schadt et al., 2008),
kidney (Wheeler et al., 2009), cell lines from asthma patients (Dixon
et al., 2007; Moffatt et al., 2007) blood (Nalls et al., 2011a), subcuta-
neous adipose tissue (Emilsson et al., 2008) and brain (Gibbs et al.,
2010; Heinzen et al., 2008; Liu et al., 2010a; Myers et al., 2007;
Webster et al., 2009). For at least some loci, eQTLs are found consis-
tently in both transformed cells and in primary tissues (Bullaughey
et al., 2009). Overall, this data might suggest that functional annota-
tion of GWAS loci can be performed in any convenient tissue.
21D.G. Hernandez et al. / Neurobiology of Disease 47 (2012) 20–28Studying brain tissue is particularly challenging because these tis-
sue samples have to be collected post-mortem and there is a high de-
gree of cellular heterogeneity. Although some eQTLs have been
nominated for brain diseases, such as MAPT in Parkinson's disease
(PD) and progressive supranuclear palsy (PSP) (Hoglinger et al.,
2011; Nalls et al., 2011b; Tobin et al., 2008; Vandrovcova et al.,
2010), many nominated loci for brain phenotypes are not functionally
annotated.
To explore the tissue speciﬁcity of eQTLs, we analyzed expression
in brain and blood using SNPs abstracted from the NHGRI catalog of
GWAS. We speciﬁcally wanted to address whether it is necessary to
examine brain tissue to detect eQTLs for brain traits, including neuro-
logical diseases and psychiatric events, or whether the same informa-
tion could be obtained from a more accessible tissue such as blood.
We ﬁnd that while many eQTLs are shared between blood and
brain, there are speciﬁc instances, not always simply related to tissue
speciﬁc gene expression levels, where the tissue studied limits detec-
tion of eQTLs.
Materials and methods
Samples
Fresh, frozen tissue samples from the frontal lobe of the cerebral
cortex and from the cerebellum were obtained from neurologically
normal Caucasian subjects. Genomic DNA was extracted using phe-
nol–chloroform and RNA using Trizol from subdissected samples
(100–200 mg). Peripheral blood specimens were collected using
PAXgene tubes. RNA was extracted from peripheral blood samples
using the PAXgene Blood mRNA kit (Qiagen, Crawley, UK) according
to the manufacturer's instructions.
Genotyping and imputation
Genotyping was performed using the Illumina Inﬁnium Human-
Hap550 v3, Human610-Quad v1 or Human660W-Quad v1 Inﬁnium
Beadchip and common SNPs across all platforms were identiﬁed for
each sample. SNPs were excluded if they showed b95% genotypingFig. 1. Power to detect eQTLs in brain and blood. Post-hoc power calculations were performe
blood (B; 501 samples). We estimated power (y axis) at a range of minor allele frequencies (
size (Z) varying from 0.1 to 2.0 standard deviations of difference for each minor allele in an
power over brain (A) to detect the same effect size, given the lower number of samples insuccess rate per SNP, minor allele frequency (MAF) b0.01 or Hardy–
Weinberg equilibrium (HWE) p-valueb1E−7. Quality control was
carried out using PLINK v1.07 for each cohort separately prior to im-
putation and was determined by comparing the subjects reported
gender with the genotypic gender determined using PLINK's check
sex algorithm.
Ethnicity and cryptic relatedness was determined using Identity-
by-State (IBS) clustering and multidimensional scaling analyses
within PLINK using genotypes that had been merged with data
from HapMap Phase III, ASW, TSI, CEU, JPT, CHB and YRI populations
[http://hapmap.ncbi.nlm.nih.gov/]. The subset of SNPs used was
shared across studies, using only common SNPs that are not corre-
lated within a 50 SNP sliding window at an r2>0.20, with each win-
dow overlapping by 5 SNPs. Samples were clustered using
multidimensional scaling, removing outliers>3 standard deviations
from the mean component vector estimates for C1 or C2 for the
combined CEU and TSI samples. Cryptically related samples were
excluded after pairwise identical by descent estimates were calcu-
lated, excluding any samples sharing greater than a 0.15 proportion
of alleles.
Markov Chain based haplotyper (MACH 1.0.16) was used to im-
pute non-assayed genotypes for blood and brain datasets indepen-
dently using the June 2010 release of the 1000 Genomes Project
build-36 reference panel, using default settings for MACH. Imputed
SNPs were excluded from the analysis if their minor allele frequency
(MAF) was b0.01 and if their r2 was b0.3.GWAS SNPs
Trait and disease associated SNPs were extracted from the NHGRI
catalog of published GWAS at http://www.genome.gov/gwastudies/
on July 30th 2011. Analyses were restricted to the following criteria:
discovery p-valueb5E−08, initial sample size >1000 (or 1000
cases in binomial analyses), replication sample size >500 (or 500
cases in binomial analyses), number of SNPs >100,000, samples of
European ancestry and risk allele frequency of SNP(s) greater or
equal to 0.01.d for sample sizes that we achieved after quality control in brain (A; 399 samples) or in
x axis) for each sample series. Each colored line represents a different normalized effect
additive model. The steeper power curves for the blood series (B) indicate improved
the former series.
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Expression proﬁling was performed largely as previously de-
scribed (Gibbs et al., 2010). RNA was biotinylated and ampliﬁed
using the Illumina® TotalPrep-96 RNA Ampliﬁcation Kit and directly
hybridized onto HumanHT-12_v3 Expression BeadChips. Where pos-
sible, the same RNA samples were used from our previous study that
used HumanRef8 Expression BeadChips. Raw intensity values for each
probe were normalized using cubic spline in BeadStudio (Illumina)
then log2 transformed. Individual probes were included in analysis
if they were detected (Pb0.01) in more than 95% of samples in the
series.
To deﬁne probes within +/−1 MB of SNPs, probes were re-
annotated using ReMOAT (http://www.compbio.group.cam.ac.uk/
Resources/Annotation/). Ambiguous probes that mapped to multiple
positions, or were identiﬁed as having design problems in ReMOAT,
were excluded from subsequent analyses. To remove potential bias
resulting from polymorphisms, all probes that included an analyzed
SNP within the 50mer probe were removed.
Expression QTL analyses
Startingwith 447 subjects in the brain series, after data normalization
and quality control, the brain mRNA dataset included 399 samples and
~9000 mRNA probes that were detected in >95% of all samples. The
blood dataset started with 712 samples, of which 501 passed all our QC
steps; 5094 mRNA probes were detected in >95% of samples.
In each brain region, mRNA probes within 500 kb of the chromo-
somal location of each SNP were incorporated into linear regression
modeling using MACH2QTLv1.08. Estimates of the association be-
tween the allelic dose of each SNP as a predictor of proximal gene ex-
pression levels were generated. These linear regression models were
adjusted for biological covariates of age at death and gender, the ﬁrst
2 component vectors frommultidimensional scaling, as well as meth-
odological covariates including post-mortem interval (PMI), tissue
bank and hybridization batch. SNPs with fewer than 3 minor homozy-
gotes detected (based on either genotyped SNPs or maximum likeli-
hood genotypes from imputation) were excluded from analyses. A
consensus set of results was extracted from the frontal cortex, cere-
bellum and blood eQTL datasets with identical overlapping combina-
tions of GWAS SNPs and proximal cis mRNA probes.
Signiﬁcant associations were determined within each tissue type
using a 5% FDR adjustment for multiple testing. Proportions of tested
associations were calculated per tissue based on this subset of the
eQTL results, and were compared using simple chi-squared tests.
Case studies of speciﬁc loci
Identical statistical models were utilized to test our ability to detect
known-associated eQTLs in previously published reports in tissues not
previously investigated in GWAS. Results for these loci were mined for
all associations within each+/−500 kb region around top SNPs within
each locus from the published GWAS within each tissue.
Results
Power to detect eQTLs in large blood or brain datasets
Directly comparing expression datasets derived from brain and
whole blood in human samples is difﬁcult because brain samplesFig. 2. Comparative gene expression in blood and in brain. (A–C) Normalized gene expressi
population and ranked such that 1.0 is the highest expressed gene. Where genes were detec
compare expression in blood versus frontal cortex (A) or cerebellum (B), or to compare fro
tween the pairs of tissue. (D–F) Similar plot but for percentile rank of the variance in expres
(E), or frontal cortex and cerebellum (F).are taken post-mortem whereas blood samples are routinely taken
during life. Therefore, we used two large, well-powered series from
different sets of individuals to maximize our ability to ﬁnd eQTLs in
each tissue type. For brain, we expanded our previous dataset
(Gibbs et al., 2010) in frontal cortex and cerebellum and obtained
whole blood from 712 individuals from the InCHIANTI study (Wood
et al., 2011). For consistency, we used the same expression array plat-
form (Illumina HT-12 beadchips containing 48,000 probes) for all
samples. After quality control, the brain mRNA dataset included 399
samples with data at 9000 probes. The blood dataset included 501
samples containing expression data from 5094 probes. Following im-
putation and quality control, ~2.2 million SNPs were available for
analysis in all sample sets.
Because the ﬁnal number of samples within the blood and brain
groups differed, we performed post-hoc power calculations to com-
pare ability to detect eQTLs (Fig. 1). Based on our previous work in
brain (Gibbs et al., 2010), the strength of the association varies sub-
stantially for different eQTLs. Therefore, we estimated power over a
range of minor allele frequencies and of effect sizes for the eQTLs,
using Z as a measure of effect size standard deviations of difference
for each minor allele under an additive model. As an example of
power in the two datasets at a realistic pair of these parameters, the
blood dataset had 98.8% power to detect eQTLs at an effect allele fre-
quency of 0.2 and an additive effect size of Z=0.5 whereas the brain
dataset had 93.9% power to detect the same magnitude of effect. This
analysis demonstrates that the difference in power in the two data-
sets is minimized as the fraction of true eQTL effect sizes rises. For
eQTLs with moderate effect sizes (Z>0.2) we were reasonably pow-
ered in both series; therefore, we proceeded to compare the ability
to detect eQTLs in both datasets.Gene expression in blood versus brain in human populations
It is expected that gene expression proﬁles would be divergent be-
tween blood and brain tissues but similar for two brain regions. To
test this, we ranked as percentiles the normalized gene expression
values averaged for all subjects, setting non-detected probes to zero.
Gene expression values were shown to be highly divergent between
blood and either frontal cortex or cerebellum tissue for a large num-
ber of genes that were only detected reliably in one tissue or the
other (Figs. 2A,B). In contrast, gene expression was more similar be-
tween frontal cortex and cerebellum and there were fewer uniquely
expressed genes (Fig. 2C). Analysis using percentile ranked variance
rather than mean values for each probe yielded similar results
(Figs. 2D–F), showing that mean expression and variance in expres-
sion were closer in the two brain regions than in blood.
eQTL discovery for genes expressed in blood and brain
We next examined the relative ability of the three datasets to de-
tect eQTLs from regions nominated in GWAS. We abstracted SNPs as-
sociated with human traits based on the NHGRI catalog of GWA,
yielding1366 loci. Of these, 783 SNPs passed the criteria of having a
replicated association with traits or diseases and being within
0.5 MB of the chromosomal position of a probe for gene expression.
We chose the threshold of 0.5 MB based on previous data (Gibbs
et al., 2010) where we saw the average distance between a SNP and
signiﬁcant eQTL was 121 Kb and >90% of signiﬁcant eQTLs were
detected within 0.5 MB.on values for each probe on the microarrays were converted to mean values across the
ted in b95% of samples in the population, we set the percentile to 0. We plotted these to
ntal cortex and cerebellum (C). Each probe is color coded by the difference in rank be-
sion across the population of samples for blood versus frontal cortex (D) or cerebellum
23D.G. Hernandez et al. / Neurobiology of Disease 47 (2012) 20–28
24 D.G. Hernandez et al. / Neurobiology of Disease 47 (2012) 20–28Wemanually annotated the traits studied in each GWAS as related
to blood (176 SNPs), brain (61 SNPs) or other (546 SNPs) phenotypes
(Supplementary ﬁle 1). For example, we annotated traits associated
with neurological or psychiatric conditions as “brain” and markers
of subtypes of blood cell markers as “blood”. We then used this list
of SNPs to perform eQTL analysis. We ﬁrst performed the eQTL anal-
ysis in a uniform way by only considering the subset of probes and
SNPs detected in all tissue types, or 2929 SNP:probe pairs. This anal-
ysis identiﬁed eQTLs that were highly signiﬁcant in all three tissues
and additional eQTLs distinctly signiﬁcant in either blood or brain tis-
sues (Fig. 3). Of the shared eQTLs, three stood out as highly signiﬁcant
in all three tissues for three SNPs including a single mRNA probe,
ILMN_1695585 that maps to the RPS26 gene on chromosome
12q13.2, within 500 KB of three GWAS SNPs associated with Type 1
diabetes (False discovery rate (FDR) corrected Pb1.45×10−38 for as-
sociation with rs11171739 in the frontal cortex, Pb6.72×10−51 in
cerebellum and Pb9.46×10−67 in blood) (Barrett et al., 2009;
Cooper et al., 2008; Hakonarson et al., 2008; Todd et al., 2007). Addi-
tional signiﬁcant SNP:probe pairs found in both datasets included
SNPs associated with traits such as mean corpuscular volume
(Ganesh et al., 2009) , smoking behavior (2010), eye color (Liu
et al., 2010b), plasma levels of liver enzymes(Yuan et al., 2008) and in-
ﬂammatory bowel disease (Kugathasan et al., 2008) (Supplementary
Table 1). For ﬁfteen SNP:probe associations that were signiﬁcant in
brain and blood, the direction of effect was consistent across all three
tissues.
A divergent set of eQTLs were found in the blood dataset when
compared with cerebellum and frontal cortex (Figs. 3A,B). Several of
these eQTLs were for probe ILMN_1666206, which maps to the
GSDML gene on Chr17q12. These correlations are linked with ﬁve sep-
arate GWA studies associating Type 1 diabetes (2007; Barrett et al.,
2009; Cooper et al., 2008; Hakonarson et al., 2008; Todd et al.,
2007), Crohn's disease (Barrett et al., 2008) and Ulcerative colitis
(McGovern et al., 2010) to the same locus (Supplementary Table 1).
Additionally, the ILMN_1666206 probe has been nominated as under-
lying an eQTL in studies of asthma and white blood cell traits associ-
ated with a pro-inﬂammatory state (Moffatt et al., 2007; Nalls et al.,
2011a). The FDR corrected P value for the most signiﬁcantly associat-
ed SNP, rs2290400, with this probe was 6.41×10−32 in blood but
0.924 and 0.896 in the cerebellum and frontal cortex respectively.
To examine this phenomenon further, we compared all SNPs within
the GSDML/ORMDL3 region to the expression of ILMN_1666206 in all tis-
sues. Although expression was detected, we did not ﬁnd signiﬁcant asso-
ciations with any SNPs in the brain, but found strong associations
between probe expression and proximal SNPs in blood tissue (Fig. 4B).
This locus therefore represents an example of a blood-speciﬁc eQTL.
Conversely, a subset of SNP:probe pairs reached signiﬁcance in the
brain samples but not in blood (Figs. 3A,B and Supplementary Table 1).
For example, rs713586, which was nominated for association with
body mass index (PMID: 20935630), was signiﬁcantly associated with
the expression of ILMN_1676893 in cerebellum (FDR corrected
P=6.09x10−5) and frontal cortex (FDR corrected P=1.53×10−8) but
showed no association in blood (FDR corrected P=0.89). This probe
maps to the adenylate cyclase gene ADCY3 on chromosome 2 (Fig. 4A).
Interestingly, variation in ADCY3 has been nominated in a number of
GWAS including for alcohol dependence (Edenberg et al., 2010) and
major depression (Wray et al., 2012).
Overall this data suggests that while some eQTLs are consistent be-
tween tissues, there is a subset where a genetic effect on gene expres-
sion exists in one tissue context but not the other, despite probe
detection in both instances.
eQTL discovery for genes with expression restricted to blood or brain
Given that there were differences in gene expression between tis-
sues (Fig. 2), we next analyzed eQTLs unique to each tissue byexamining the association of GWAS SNPs with expression of probes
detected in either blood or brain but not in both (Supplementary
Table 2).
In blood, there was a highly signiﬁcant (FDR corrected
P=1.27×10−131) association between rs2549794 at a Crohn's dis-
ease locus (Franke et al., 2010) and expression of ILMN_1743145,
which maps to the LRAP/ERAP2 gene (Fig. 5A). Other associations
measurable only in the blood datasets include rs2304130 and
ILMN_2134224, and rs6120849 and ILMN_2402805. These SNPs
were nominated as associated with measurements of total choles-
terol and protein C respectively in plasma (Tang et al., 2010;
Waterworth et al., 2010).
We also found a series of signiﬁcant associations in brain and not
blood. Several of these associations were probes on chromosome 12
associated with rs11171739 or rs1701704, two SNPs nominated for
Type-I diabetes. Additional associations included a series of SNPs on
chromosome 17. Previous studies have noted an effect of chromo-
some17 SNPs on expression of the MAPT gene that is associated
with risk of PD and PSP (2011; Hoglinger et al., 2011). We therefore
examined expression of ILM_1710903, which maps within the coding
sequence of MAPT, with association of SNPs across Chr17 and saw ro-
bust signals in both the frontal cortex and cerebellum (Fig. 5B). This
effect was driven by the H1/H2 haplotype across the MAPT locus as
conditioning the analysis on a proxy SNP decreased the apparent
eQTL signal.
Collectively, these results show that while some eQTLs are
shared across tissues, there are examples where restricted expres-
sion levels in one tissue limit the ability to detect signiﬁcant
associations.
Overall ability to detect eQTLs depends on tissue type and
gene expression
We next compared the proportions of eQTLs found in the three
sample series and considered whether these were associated with
brain, blood or other phenotypes (Table 1). In the analysis restrict-
ed to probes detected in both blood and brain tissues, 125 eQTLs
were found within 500 KB of any GWA SNP in blood, versus 40
eQTLs found in the brain dataset. Of these, 21 signiﬁcant eQTLs
were found in the blood dataset for blood traits, while 16 eQTLs
were found in blood for brain traits. Six signiﬁcant eQTLs were
found in the brain, counting either cerebellum or frontal cortex,
for brain traits and an additional six eQTLs were found in brain
for blood traits out of 40 total signiﬁcant associations. The propor-
tions of blood and brain traits with detected eQTLs were similar
in blood and brain samples (two tailed Z-test, P=0.18, 1.0
respectively).
We performed independent analyses of probes that were
only detected in one tissue as more probes were tested in brain
(1877 in frontal cortex and 1853 in cerebellum) than in blood
(413). There were 107 signiﬁcant associations in cerebellum and 90
in frontal cortex compared to 21 in blood but we did not ﬁnd over-
representation of traits annotated as brain related in the brain
datasets (Table 2).
Discussion
We have performed an eQTL analysis using SNPs from the
NHGRI catalog of GWAS in two tissue types, blood and brain (fron-
tal cortex and cerebellum). The nominated SNPs are associated
with a variety of human traits, including diseases, physiological
markers such as blood cell numbers and continuous traits such as
height. We speciﬁcally addressed whether it is necessary to exam-
ine brain tissue to detect eQTLs for brain phenotypes or whether
the same information could be obtained from blood. We ﬁnd that
while many eQTLs are shared between blood and brain tissues,
25D.G. Hernandez et al. / Neurobiology of Disease 47 (2012) 20–28there are speciﬁc instances, not always simply related to gene ex-
pression levels, where the detection of eQTLs is limited by the tis-
sue studied.
A small number of eQTLs are detectable in all three datasets test-
ed. A proportion of these common eQTLs demonstrated strong ef-
fect sizes, such as SNPs associated with Type 1 diabetes on
chromosome 12 (Barrett et al., 2009; Burton et al., 2007; Cooper et
al., 2008; Hakonarson et al., 2008; Todd et al., 2007) or associated
with smoking behavior on chromosome 19 (Furberg et al., 2010).
We have therefore demonstrated that coincident eQTLs exist be-
tween blood and brain tissues and therefore discrete eQTLs are
found in more than one human primary tissue as previously sug-
gested (Bullaughey et al., 2009; Ding et al., 2010; Greenawalt et
al., 2011).
There were eQTLs that could be detected only in one tissue type
and in some cases these are due to differences in gene expression.
This is true for genes such as MAPT, which encodes for the tau pro-
tein that is expressed largely in post-mitotic neurons. Therefore,
there will be cases where, when interrogating GWAS data it will
be important to examine the target tissue of interest, thus afﬁrming
the need to look at brain for studies related to neurological or psy-
chiatric phenotypes.
Of greater interest is that we also found a subset of eQTLs that
appear to be tissue speciﬁc, despite the probes being reliably
detected in all samples series. It is possible that genetic variants
can affect expression levels exclusively in a subset of tissues. For ex-
ample, gene expression may be altered in a tissue- and timing-
speciﬁc manner by cis-regulatory elements (Cooper et al., 2008). In
this case, although multiple tissues may be permissive for expres-
sion, different -cis regulatory elements are being employed in each
tissue and lead to quantitatively different expression levels. Under-
standing why there are examples where differences in expression
do not explain eQTL detection in a simple way will be an important
question for future studies.
One caveat to these studies is that direct comparison of datasets
derived from separate tissue types with differential ascertainment
methods is difﬁcult. Speciﬁcally, the brain samples were taken from
deceased subjects whereas blood samples were drawn in life. Howev-
er, post-mortem interval has been shown not to be a major confound
within brain expression data (Gibbs et al., 2010; Trabzuni et al., 2011)
and we corrected for this and other known methodological variables
in the statistical model. However, because the samples used here
were from different individuals, we cannot exclude that we are
detecting rare alleles and/or genetic variants on a background of com-
mon SNPs. As demonstrated by power analysis, the current dataset is
not powered to directly detect rare alleles but has good power to de-
tect relatively large eQTL effect sizes. Therefore, this analysis per-
forms best for loci that are tagged by common variants and where
the effect of the minor allele on expression is relatively large. It is
also important to note that in the present study, we limited our anal-
ysis to transcripts within a relatively narrow (0.5 MB) window
around each SNP. This is larger than the average distance between
SNP and associated transcript of 121 Kb (Gibbs et al., 2010) but may
inadvertently omit true eQTLs at larger distances while maintaining
power. Larger series would be needed to expand the analyses to
more distal effects.Fig. 3. Similar and distinct SNP:probe associations in brain and blood.Each point shows
comparisons of− log[10] of FDR corrected p values for identical SNP and probe combi-
nations across all 3 tissues investigated, comparing blood with frontal cortex (A) or
cerebellum (B) and frontal cortex to cerebellum (C). Size of points is scaled to the com-
bined FDR corrected p values after − log[10] transformation. Points are colored by the
associated phenotypes, where brain traits are shown in orange, blood traits in green
and others in blue.
Fig. 4. Blood and brain speciﬁc eQTLs in probes that are detected in all tissues. (A) Similar locus plot for ILMN_167893, which maps to ADCY3 and reveals a highly signiﬁcant signal in
the brain samples but no signiﬁcant p values in blood, despite adequate detection of the probe in all tissues. (B) Plot of SNPs along the Chr17 region that includes the GSDML and
ORMDL3 genes showing− log[10]P values for association of each SNP with expression of Illumina probe ILMN_1666206, which maps to the GSDML gene. Despite having signiﬁcant
detection in all three tissues, there was a strong signal for blood (red) but not in either of cerebellum (blue) or frontal cortex (green).
26 D.G. Hernandez et al. / Neurobiology of Disease 47 (2012) 20–28Further dissection of such loci will likely require deep sequencing
of the genome for many individuals and additional large-scale
studies. One general limitation of hybridization based arrays is that
detection of low expression genes is difﬁcult, which may be over-
come by RNA sequencing in the future. In addition to both of these
technological developments, eQTL surveys such as the one pre-
sented here will need to be repeated as the number of SNPs nomi-
nated by GWAS studies increases. This is perhaps particularly true
for brain related phenotypes. Although we did not ﬁnd that there
were signiﬁcantly more eQTLs for brain phenotypes using brain
expression data, the number of replicated GWAS ‘hits’ for neurolog-
ical and psychiatric conditions is still quite small and we might
expect the brain to be more sensitive as the number of replicated
loci increases. We have not tested all possible SNPs in the current
analysis to maintain power to detect signiﬁcant associations, but
such analyses could be performed on an ad hoc basis for nominated
SNPs in future GWASwithout the loss of power caused by testing the
whole genome.
Overall, we demonstrate a number of clear and key examples
where brain tissue is required for eQTL discovery. We conclude that
functional studies in one tissue have the capacity to inform our un-
derstanding of regulatory variation in general, but that there aresufﬁcient numbers of counter-examples to suggest that for neurological
and psychiatric traits we should continue to examine gene expression
in the brain.Datasets
Datasets have been submitted to GEO: accession # GSE36192.
Supplementary data to this article can be found online at doi:10.
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Fig. 5. eQTLs in probes detected only in brain or blood. (A) SNPs along the region of Chr5 that contains the LRAP gene showing− log[10]P values for association of each SNP with
expression of Illumina probe ILMN_1743143. (B) Plot of SNPs along the Chr17 region that includes theMAPT gene for ILMN_ 1710903 in frontal cortex (upper panel) or cerebellum
(lower panel). For each tissue, we repeated the original eQTL analysis (green) but made the analysis conditional on a proxy SNP for the H1/H2 inversion haplotype (orange). The
decrease in P values after conditioning on a proxy SNP suggests that most of the signal arises from the H1/H2 haplotype.
Table 1
Counts of SNPs and SNP:probe pairs tested and signiﬁcant associations per tissue and trait for probes that were detected in all tissues.
Counts of all SNPs and probes used and their annotations as blood vs brain
All GWAS Blood Brain Other
SNPs 783 176 (22.5%) 61 (7.8%) 546 (69.7%)
SNP:probe pairs 2929 683 (23.3%) 227 (7.6%) 2019 (68.9%)
Count (% of all) of signiﬁcant associations within 500 kb of SNP
Blood 125 21 (16.8%) 16 (12.8%) 88 (70.4%)
Cerebellum 33 5 (15.15%) 5 (15.15%) 23 (69.7%)
Frontal cortex 21 3 (14.3%) 2 (9.5%) 16 (76.2%)
Table 2
Counts of SNPs and SNP:probe pairs tested and signiﬁcant associations per tissue and trait for probes that were detected in either blood or in brain.
Count (% of all) of signiﬁcant associations within 500 kb of SNP
Tissue SNPs Probes Associations tested All GWAS Blood Brain Other
Blood 648 413 658 21 5 (23.8%) 2 (9.5%) 14 (66.7%)
Cerebellum 943 1853 3924 107 21 (19.6%) 13 (12.1%) 73 (68.2%)
Frontal cortex 978 1877 3968 90 21 (23.3%) 7 (7.8%) 62 (68.9%)
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